 Akcea Therapeutics, Inc. NASDAQ: AKCA, a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing medicines to treat patients with serious and rare diseases, today reported financial results for the second quarter ended June 30, 2020. The company reported a net loss for the three and six months ended June 30, 2020 on a GAAP basis of 50 million and 92 million, respectively. On a non-GAAP basis, the company reported a net loss for the three and six months ended June 30, 2020 of 33 million and 69 million, respectively. Akcea had 390 million of cash, cash equivalents and short-term investments as of June 30, 2020. 